Fangsheng Pharmaceutical: Indomethacin raw material production inspection found to be non-compliant.

Fangsheng Pharmaceutical Announcement: The company has received a notice from the Hunan Provincial Drug Administration regarding the inspection results of the indobufen bulk drug production line at the company's new production address in the Wangcheng Economic Development Zone of Hunan Province, which do not meet the requirements. The main reason is that the production standard of intermediate 1 has not been updated to the latest version. This bulk drug was approved for market in June 2024 and has not yet been officially launched on the market, so this inspection result will not have a substantial impact on the company's production and operation. The company has made corrections and will reapply for inspection as soon as possible.